We are live on ! Find out more
ARDS

Aridis Pharmaceuticals Inc. Common Stock

Delisted

ARDS was delisted on the 18th of July, 2023.

1 hedge funds and large institutions have $0 invested in Aridis Pharmaceuticals Inc. Common Stock in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 (0)

100% less capital invested

Capital invested by funds: $1 → $0 (-$1)

Holders
1
Holders Change
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ARDS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,337 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q2 2026, worth a combined $0 — down 100% from $1 a quarter earlier.

Fund positioning in ARDS was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $0 of Aridis Pharmaceuticals Inc. Common Stock stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q2 2026 and 0 closed out.

Based on aggregated 13F filings for Q2 2026.